Cogent Biosciences, Inc. Share Price
NASDAQ: COGT | Mid CapCogent Biosciences, Inc. Stock Performance
Open $42.29 | Prev. Close $41.72 | Circuit Range N/A |
Day Range $41.74 - $42.73 | Year Range $10.40 - $43.55 | Volume 1,27,434 |
Average Traded $42.28 |
Cogent Biosciences, Inc. Share Price Today
As of 10 August 2026, Cogent Biosciences, Inc.'s share price is $42.36. The stock opened at $42.29, compared to its previous close of $41.72. During today's trading session, Cogent Biosciences, Inc.'s share price traded between $41.74 and $42.73, with an average price of $42.24. Over the past 52 weeks, the stock has recorded a high of $43.55 and a low of $10.40. In terms of performance, Cogent Biosciences, Inc.'s share price has risen by 8.94% over the last six months and is up 250.37% on a year-on-year basis.
Cogent Biosciences, Inc. Share Price Chart
Cogent Biosciences, Inc. Stock Fundamentals & Key Indicators
Market Cap $5.46B | PE Ratio (TTM) -19.61 | Dividend Yield N/A |
EPS (TTM) $-2.16 | Revenue (TTM) -$333.36M | Return On Equity (TTM) -51.69% |
Profit Margin 98.67% | Debt to Equity 0.10 | Quarterly Earnings Growth YoY -14.58% |
Cogent Biosciences, Inc. Quarterly Profit & Loss
All figures in USD
Cogent Biosciences, Inc. Annual Profit & Loss
All figures in USD
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Cogent Biosciences, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $38.40 | $42.38 | +8.92% |
Jul 2026 | $38.71 | $38.91 | +0.52% |
Jun 2026 | $34.90 | $38.71 | +10.68% |
May 2026 | $36.06 | $34.98 | -2.28% |
Apr 2026 | $37.66 | $35.79 | -7.04% |
Mar 2026 | $38.09 | $38.50 | -0.99% |
Feb 2026 | $36.41 | $38.88 | +8.22% |
Jan 2026 | $35.73 | $35.93 | +1.15% |
Dec 2025 | $39.43 | $35.52 | -11.73% |
Nov 2025 | $16.66 | $40.24 | +146.43% |
Oct 2025 | $14.24 | $16.33 | +13.71% |
Sep 2025 | $12.03 | $14.36 | +18.78% |
COGT Share Price FAQs
What is Cogent Biosciences, Inc. share price today?
What is the 52 week high and 52 week low of Cogent Biosciences, Inc. stock?
What is COGT's market capitalisation today?
What is COGT's net income for the last quarter?
What is the 5 year returns of COGT?
What is the high & low stock price of COGT today?
Can I buy COGT shares in India?